Regeneron

Regeneron is a leading biotechnology company focused on discovering and developing antibody-based medicines, with approved therapies spanning ophthalmology, oncology, immunology, and infectious disease, including the blockbuster drugs Eylea and Dupixent. The company operates the Regeneron Genetics Center, one of the largest human genetics sequencing efforts in the world, generating petabyte-scale genomic datasets that inform drug target discovery and validation. Engineering challenges include building bioinformatics pipelines for population-scale genomic analysis, developing ML models that predict protein structure and antibody binding properties, and maintaining the computational infrastructure required for large-scale genetic association studies. Regeneron's hiring patterns signal the pharmaceutical industry's deepening investment in computational biology and data science, with increasing demand for engineers who can build production systems around genomic data and integrate computational predictions into the drug discovery pipeline.